Clozel resumes CEO role at Idorsia, Mestag builds C-suite  

After serving as CEO of Idorsia Ltd. (SIX:IDIA) for about nine months, Srishti Gupta stepped down from her position this week, with chairman and former CEO Jean-Paul Clozel returning to the role on an interim basis. Gupta is also leaving her board seat, which she had held since 2021.

An 18-year veteran of McKinsey & Co., Gupta arrived in the midst of a difficult period that included a cash crunch and a restructuring. Still, Idorsia reported that sales of insomnia drug Quviviq daridorexant more than doubled to CHF134 million ($173.3 million) in 2025, and the company continues to advance a pipeline that includes therapies for Fabry disease and psoriasis...